On May 22, 2023 NatureWise reported that its new drug, NBM-BMX, received USFDA approval on January 4th, 2023 to proceed in Phase Ib/II clinical trials in newly diagnosed GBM (Press release, NatureWise Biotech & Medicals, MAY 22, 2023, View Source [SID1234631916]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Glioblastoma multiforme is one of the most aggressive, invasive, and deadly malignancies. More than 60% of newly diagnosed GBM patients do not respond to standard treatment. Our studies demonstrated that NBM-BMX is a new therapeutic approach with the potential for addressing this need for safer, more effective treatment options for GBM.